Phase 1 Study of Dual Imaging Using 111In-Panitumumab SPECTCT and Panitumumab-IRDye800 Fluorescence to Detect Head and Neck Squamous Cell Carcinoma During Surgery

What this Trial Is About

Researchers are evaluating the safety and effectiveness of two imaging techniques, indium In 111 panitumumab 111In-panitumumab with SPECTCT and panitumumab-IRDye800 fluorescence imaging during surgery, for detecting disease in patients with head and neck squamous cell carcinoma. This phase I trial focuses on how well these dual imaging agents identify tumor cells and lymph nodes, aiming to improve disease detection during surgical removal. The study is sponsored by the Vanderbilt-Ingram Cancer Center and targets patients scheduled for surgery with this type of cancer. Participants receive panitumumab-IRDye800 intravenously over 15 minutes followed by an IV dose of 111In-panitumumab on day 0. Between days 1 and 5, patients undergo SPECTCT scans before having standard surgical tumor removal combined with fluorescence imaging. This dual modality imaging approach combines radioactive and fluorescent agents to help surgeons better visualize cancerous tissue during operations. During the study, researchers monitor patients for adverse effects up to day 15 to assess safety. They also evaluate the imaging agents sensitivity and specificity in detecting tumor margins and involved lymph nodes, with follow-up outcome measurements extending up to four years. Participants undergo standard blood tests and imaging, and their progress is closely observed to determine how well the imaging techniques work and their safety over time.

Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer